Please ensure Javascript is enabled for purposes of website accessibility

England Officially Rejects AstraZeneca's Lung Cancer Drug

By Mark Prvulovic - Jan 22, 2020 at 4:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite the company's best efforts, England's top regulators say the drug is too expensive.

One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca's (AZN 2.59%) lung cancer drug Tagrisso.

A few months ago, the pharmaceutical giant argued that the drug should receive approval as the first line of defense for patients with EGFR-positive non-small cell lung cancer -- about 10% of all lung cancer patients. Clinical data has shown that Tagrisso can delay cancer growth for almost 19 months, in comparison to the 10 months that a pair of rival drugs were able to demonstrate. However, NICE found the drug to be too expensive relative to its effectiveness, costing 5,770 pounds ($7570) for a 30-day supply.

A patients and a doctor going over a lung scan.

Image source: Getty Images.

"The cost-effectiveness estimates vary from slightly below to above the range considered to be a cost-effective use of NHS resources," read an official statement from NICE.

Continuing regulatory scrutiny

The decision is a harsh blow to AstraZeneca. Tagrisso was its top-selling treatment for most of 2019, generating $2.3 billion in the first nine months of the year. The drug received approval in the U.S. back in April 2018, with additional approvals from Canada and the EU following shortly after.

NICE has rejected a number of drugs from coverage recently based on cost-effectiveness criteria. Earlier today, the watchdog also published a note rejecting Astellas Pharma's gilteritinib for patients with myeloid leukemia. Johnson & Johnson's ulcerative colitis drug, Stelara, also fell under scrutiny by NICE on Wednesday, although the company still has until mid-February to provide new evidence that would support a decision to cover it.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.21 (2.59%) $1.67
Johnson & Johnson Stock Quote
Johnson & Johnson
$176.98 (1.75%) $3.04
Astellas Pharma Inc. Stock Quote
Astellas Pharma Inc.
$15.45 (-0.38%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.